Response of Lactobacillus casei BL23 to phenolic compounds

Aims: To determine the inhibitory effect of phenolic compounds on Lactobacillus casei BL23, the role of two component signal transduction systems (TCS) and the response of Lact. casei BL23 to p‐coumaric acid. Methods and Results: Growth of Lact. casei BL23 and 17 derivative strains defective in each TCS harboured by this strain in the presence of p‐coumaric acid, ferulic acid, caffeic acid or methyl gallate was monitored. Furthermore, changes in the protein content of Lact. casei BL23 when exposed to p‐coumaric acid were evaluated by 2D‐SDS‐PAGE. Eleven proteins differentially expressed in the presence of p‐coumaric acid were detected. Six of them could be identified: ClpP and HtrA, involved in protein turnover and folding, acetyl‐CoA carboxylase, involved in lipid metabolism, and an arginyl‐tRNA synthetase were more abundant, whereas PurL and PurN, involved in purine biosynthesis, were less abundant. Conclusions: No significant differences were observed between the parental strain and the TCS‐defective mutants. p‐Coumaric acid elicited a response against membrane and cytoplasmic damages. Significance and Impact of the Study: The inhibitory effect of phenolic compounds on Lact. casei BL23 has been determined. For the first time, cytoplasmic proteins presumably involved in the response of Lact. casei BL23 against p‐coumaric acid have been identified.     

Identification of a second Klotho interaction site in the C terminus of FGF23

1. Download : Download high-res image (142KB)
2. Download : Download full-size image

     

FGF23, alpha-Klotho and vitamin D mediated calcium-phosphate metabolism in haemodialysis patients

BackgroundKlotho is a prote˝in that acts as a co-receptor for FGF23. FGF23-Klotho axis has great importance regarding the regulation of mineral metabolism by kidneys. In this study, we analysed FGF23, Klotho, 1,25-dihydroxyvitamin D3, 25-hydroxyvitamin D, parathormone, Calcium and Phosphate levels of haemodialysis patients in order to investigate the nature of the mineral metabolism disruption in chronic kidney diseases.MethodsSixty haemodialysis patients and 34 healthy controls were included in the study. Serum iFGF, cFGF, and soluble Klotho were analysed using ELISA kits. Moreover, 1,25-dihydroxyvitamin D3 was determined using LCMS/MS. Calcium, phosphate, iPTH and 25-hydroxyvitamin D were measured using autoanalyzers.ResultsIn haemodialysis patients, iFGF23, cFGF23, iPTH and P levels were significantly higher, and 1,25-dihydroxyvitamin D3, Klotho and Ca levels were significantly lower compared with the control group. There was no significant difference in the 25-hydroxyvitamin D levels.ConclusionsOur study showed that lack of sufficient amounts of Klotho is crucial for mineral metabolism disruptions seen as a complication of chronic kidney diseases. Despite the high levels of the hormone, FGF23 is unable to accomplish its function properly, likely due to deteriorated kidney function in haemodialysis patients.     

妊娠期糖尿病患者血清NRG4、FGF-23、PGRN水平及其临床意义

摘要 目的：探讨妊娠期糖尿病患者血清神经调节蛋白4(NRG4)、成纤维细胞生长因子-23(FGF-23)、前颗粒体蛋白(PGRN)水平及其临床意义。方法：选择2018年4月至2019年11月我院诊治的90例妊娠期糖尿病患者作为糖尿病组,选择同期在我院进行健康体检的90名健康孕妇作为对照组。检测两组血清NRG4、FGF-23、PGRN水平,血脂指标[高密度脂蛋白（HDL）、总胆固醇（TC）、甘油三酯（TG）和低密度脂蛋白（LDL）]水平,肝功能指标[谷草转氨酶（AST）、谷丙转氨酶(ALT)]水平,血糖和胰岛素指标[空腹血糖（FPG）、空腹胰岛素(FINS)]水平,并计算抗胰岛素抵抗指数(HOMA-IR)、胰岛素敏感性指数（ISI）和胰岛?茁细胞功能指数(HOMA-β)。分析各临床指标间的关系。结果：与对照组相比,糖尿病组体质量指数（BMI）、TG、TC、FPG、FINS、HOMA-IR、NRG4、FGF-23、PGRN明显升高（P<0.05）,ISI和HOMA-β明显下降（P<0.05）。血清NRG4、FGF-23、PGRN与ISI和HOMA-β均呈负相关（P<0.05）,与BMI、TG、TC、FPG、FINS、HOMA-IR均呈正相关（P<0.05）。TG与NRG4表达联系密切（β=0.007,P<0.05）,ISI和HOMA-IR与FGF-23表达联系密切（β=-6.674、0.048,P<0.05）,FPG和TC与PGRN表达联系密切（β=22.308、0.507,P<0.05）。结论：妊娠期糖尿病患者血清NRG4、FGF-23、PGRN水平异常升高,并参与妊娠期糖尿病患者的糖脂代谢和胰岛素抵抗,检测其水平有助于评估妊娠期糖尿病的糖脂代谢异常情况。     

Localization of nucleolar phosphoproteins B23 and C23 during mitosis

Nucleolar phosphoproteins B23 and C23 were simultaneously localized in unsynchronized male rat-kangaroo PtK2 cells during mitosis using a mouse monoclonal antibody against protein B23 and a rabbit antibody against protein C23. The distribution of proteins B23 and C23 during mitosis was compared with the distribution of the silver staining protein. During interphase, proteins B23 and C23 were both localized to the nucleolus. As the nucleolus disappeared in prophase, the distribution of protein B23 became nucleoplasmic, whereas most of protein C23 remained associated with the disappearing nucleolus. Throughout metaphase and anaphase protein B23 was found associated with the chromosomes, whereas protein C23 seemed to disappear. When the nucleolus reformed during telophase, protein C23 appeared first in ‘prenucleolar bodies’ and then in the nucleolus, whereas protein B23 did not appear in the nucleolus until late telophase or early G1 phase. Silver staining during mitosis closely paralleled the distribution of protein C23, supporting previous conclusions that protein C23 is a silver staining nucleolus organizer region (NOR) protein [19, 20].     

Rab23 研究进展

Rab23为小GTP结合蛋白,是Ras超家族Rab家族成员,其突变可引起小鼠开脑综合征(open brain syndrome),因此又称为opb基因.它是Sonic hedgehog信号通路的负调控因子,在不同肿瘤中发挥不同作用,并参与机体组织器官的发育和分化.它可能通过转运细胞内蛋白发挥相关作用.     

Rab23研究进展

Rab23为小GTP结合蛋白,是Ras超家族Rab家族成员,其突变可引起小鼠开脑综合征（openbrain syndrome）,因此又称为opb基因。它是Sonic hedgehog信号通路的负调控因子,在不同肿瘤中发挥不同作用,并参与机体组织器官的发育和分化。它可能通过转运细胞内蛋白发挥相关作用。     

脂质代谢在乳腺癌发病中的作用

乳腺癌已经成为全球第一大癌症,其发病机制及治疗方法的探索越来越受到人们重视。脂质代谢异常是癌细胞中最突出的代谢改变之一,探索乳腺癌细胞中脂质代谢的改变,以寻找新的诊断指标和治疗靶点是至关重要的。本文从脂肪酸代谢、甘油三酯代谢、胆固醇代谢和脂质代谢信号通路4个方面介绍脂质代谢异常在乳腺癌中的研究进展,为靶向脂质代谢治疗乳腺癌提供新思路和新方法。     

A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes

Treatment of type 2 diabetes mellitus (T2DM) patients with pioglitazone results in a more favorable lipid profile, and perhaps more favorable cardiac outcomes, than treatment with rosiglitazone. Pioglitazone treatment increases VLDL-triacylglycerol clearance, but the role of de novo lipogenesis (DNL) has not been explored, and no direct comparison has been made between the thiazolidinediones (TZDs). Twelve subjects with T2DM and hypertriacylglyceridemia were randomized to either rosiglitazone or pioglitazone treatment. Stable isotope infusion studies were performed at baseline and after 20 weeks of treatment. Both treatments reduced glucose and HbA(1c) concentrations equally. Pioglitazone treatment resulted in a 40% reduction in hepatic DNL (P < 0.01) and in a 25% reduction in hepatic glucose production (P < 0.05), while rosiglitazone did not significantly change either parameter, although comparisons of changes between treatments were not significantly different. These pilot results indicate that pioglitazone reduces hepatic DNL while rosiglitazone does not. Larger follow-up studies are required to confirm differential effects of these agents definitively. The reduction in DNL may underlie altered assembly or atherogenicity of lipoprotein particles and may reflect PPARalpha or other non-PPARgamma actions on the liver by pioglitazone. These differences might help explain previously reported differences in lipid profiles and cardiovascular disease outcomes for rosiglitazone and pioglitazone.